This is an ongoing trade, 3rd week in running. As much as I want to own the stock at $250 and below, I also want to lower the cost basis. STO next week $TSLA 20250328 245.0 PUT$ for 7.55, BTC this week $TSLA 20250321 245.0 PUT$ at 0.10. Net gain $738 from last week sales (see other post) This week was quite a scare when it dip to low $222 prior to Feds IR mtg and Mark 'Liar' Rober fake Lidar crash. I was ready for assignment, but seems like lots of buyers decided to snag the bargain after Elon 'all-in' Robo taxi reaffirmation and lotsa positive FSD videos from China testers. I think this is the lowest level, going fwd it
$Direxion Daily FTSE China Bull 3X Shares(YINN)$ Take profits from earlier run up and will be buying back at the low of $44. Sometimes, we can do a bit of trading from extra stock holdings. Good luck
$Tesla Motors(TSLA)$ Tesla’s technical edge remains intact. Its vertical integration—evident in scalable 4680 battery production at multiple Gigafactories—drives significant cost reduction and higher efficiency. Upcoming hardware upgrades (HW5) and Dojo’s 400% boost in AI training capacity further enhance FSD performance. Meanwhile, the next-gen vehicle platform (“Redwood”) is designed to slash production costs for mass-market affordability, positioning Tesla strongly for long-term growth.  
$Stryker(SYK)$ 's diversified portfolio, strong brand recognition, and history of innovation make it a relatively resilient company in the face of economic downturns. Additionally, the demand for medical devices, particularly in the orthopedic and spinal care markets, tends to be less cyclical and more stable. Overall, Stryker is a solid company with a strong track record of financial performance and innovation. While it's not immune to market fluctuations, it's a relatively recession-resistant stock that can provide a stable foundation for a diversified portfolio.
Dollar Tree (DLTR): Why the Dip Could Be a Buying Opportunity
$Dollar Tree(DLTR)$ Current Performance & Valuation Price: $66.75 (up 3.34% today, but down 51.3% from 52-week high of $137.14). Valuation: P/E Ratio (TTM): Negative (-13.82) due to recent losses. Price-to-Sales (TTM): 0.46x – well below industry peers, signaling undervaluation. Analyst Target Price: $82.88 (mean), implying 24% upside potential . Catalysts for Recovery Upcoming Q4 Earnings (March 26) Oppenheimer expects EPS of $2.21 vs. consensus $2.18. A beat could spark momentum. Strategic review of Family Dollar division may unlock shareholder value (e.g., spin-off or sale). Tariff Mitigation Efforts: 40% of imports sourced from China; management plans to diversify suppliers to offset $0.40/share tariff impact. Store Optimizati
$NVIDIA(NVDA)$ Innovation is the key to growth and development. Although GenAI has always been largely revolves around talks hype or fancy use cases. It needs to penetrates into everyone daily lives to create the same effect as the industrial age. Given the cost of technology falling as adoption continues to improve, it will reach a point where it's readily accessible for the vast majority of us. That's when we will need its application becoming common just like how emails changed the way we walk and communicate. Let's see how long it will take us! In this coming 5 years?
$Advanced Micro Devices(AMD)$ it's really coming back guys! Just wait for this new week start later on! I'm sure it will fly to the moon later ! Let's see !